Related Experiment Video
Updated: Jul 31, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
A modified large sample approach in the assessment of population bioequivalence
1Quality Management and Technology Group, Dupont, Wilmington, Delaware 19898, USA.
Abstract:
The U.S. Food and Drug Administration (FDA) requires pharmaceutical companies to show bioequivalence between different formulations or generic companies to show bioequivalence between generic drugs and brand drugs before approval. In a recent FDA guidance on bioequivalence, new criteria were proposed for assessment of population and individual bioequivalence. In this article, computer simulation is used to compare a modified large sample (MLS) upper bound for the population bioequivalence ratio with the bootstrap upper bound recommended by the FDA. The comparison criteria are the ability to maintain the stated confidence level and the estimated power of tests based on these bounds.
More Related Videos
08:27Large-Scale Multi-Omics Genome-Wide Association Studies (Mo-GWAS): Guidelines for Sample Preparation and Normalization
Published on: July 27, 2021
08:58Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
Published on: October 17, 2025
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence studies: Biowaivers
Bioequivalence Data: Statistical Interpretation
Bioequivalence of Drugs: Drugs with Multiple Indications